Codagenix Inc., a US-based clinical-stage synthetic biology company, announced on Tuesday that it has named Kimber Poffenberger, PhD as its new chief strategy officer.
Dr Poffenberger has more than 20 years of strategic and regulatory leadership experience at pharma and biotech companies. She has held the position of principal consultant at Poffenberger Regulatory Resources, senior vice president, head of Global Regulatory Affairs at Alvotech, vice president and regional US head, Global Regulatory Affairs at GSK Vaccines and as executive director, Global Vaccines Strategy at Merck. Dr Poffenberger has also served in various leadership positions at Intercell, MedImmune, and Iomai Corporation.
J Robert Coleman, PhD, MBA, Codagenix,co-founder and CEO, said, 'We are excited to welcome Kimber to Codagenix. With her distinguished track record of driving global vaccine development and history of successfully leading cross-business strategic teams, she will provide an invaluable perspective to our organisation as we continue to develop our deep clinical pipeline of live attenuated vaccines and cancer virotherapeutics. Kimber brings extensive regulatory and product expertise, which will be critical as we work to bring our medicines to the patients who need them most.'
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
Medivir and Vetbiolix report positive results from VBX-1000 Proof-of-Concept clinical study
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
ELIAS Animal Health names new chief revenue officer
Innate Pharma reports preclinical efficacy of IPH45
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval